UA117353C2 - Форми дозування ензалутаміду - Google Patents
Форми дозування ензалутамідуInfo
- Publication number
- UA117353C2 UA117353C2 UAA201503119A UAA201503119A UA117353C2 UA 117353 C2 UA117353 C2 UA 117353C2 UA A201503119 A UAA201503119 A UA A201503119A UA A201503119 A UAA201503119 A UA A201503119A UA 117353 C2 UA117353 C2 UA 117353C2
- Authority
- UA
- Ukraine
- Prior art keywords
- enzalutamide
- formulations
- disclosure provides
- hyperproliferative disorders
- provides formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699351P | 2012-09-11 | 2012-09-11 | |
| PCT/US2013/059223 WO2014043208A1 (en) | 2012-09-11 | 2013-09-11 | Formulations of enzalutamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA117353C2 true UA117353C2 (uk) | 2018-07-25 |
Family
ID=49231627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201503119A UA117353C2 (uk) | 2012-09-11 | 2013-09-11 | Форми дозування ензалутаміду |
Country Status (30)
| Country | Link |
|---|---|
| US (11) | US20140100256A1 (https=) |
| EP (6) | EP2895463A1 (https=) |
| JP (5) | JP6404217B2 (https=) |
| KR (1) | KR102225416B1 (https=) |
| CN (2) | CN109897004A (https=) |
| AU (2) | AU2013315619B2 (https=) |
| BR (1) | BR112015005432B1 (https=) |
| CA (1) | CA2884795C (https=) |
| CY (1) | CY1124729T1 (https=) |
| DK (1) | DK3725778T4 (https=) |
| EA (2) | EA033374B9 (https=) |
| ES (1) | ES2892029T5 (https=) |
| FI (1) | FI3725778T4 (https=) |
| HK (1) | HK1212701A1 (https=) |
| HR (1) | HRP20211423T4 (https=) |
| HU (1) | HUE057701T2 (https=) |
| IL (1) | IL237604B (https=) |
| IN (1) | IN2015DN02875A (https=) |
| LT (1) | LT3725778T (https=) |
| MX (3) | MX363974B (https=) |
| PH (1) | PH12015500525A1 (https=) |
| PL (1) | PL3725778T5 (https=) |
| PT (1) | PT3725778T (https=) |
| RS (1) | RS62676B2 (https=) |
| SI (1) | SI3725778T1 (https=) |
| SM (1) | SMT202100550T1 (https=) |
| TW (1) | TWI673051B (https=) |
| UA (1) | UA117353C2 (https=) |
| WO (1) | WO2014043208A1 (https=) |
| ZA (1) | ZA201501847B (https=) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6404217B2 (ja) | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| NZ744456A (en) | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| CN105377299B (zh) * | 2013-04-17 | 2018-06-12 | 西格诺药品有限公司 | 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法 |
| WO2015118015A1 (en) * | 2014-02-05 | 2015-08-13 | Lek Pharmaceuticals D.D. | Solid pharmaceutical compositions of androgen receptor antagonists |
| CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
| LT3226842T (lt) * | 2014-12-05 | 2021-03-25 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
| SG11201704267VA (en) | 2014-12-05 | 2017-06-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| HUE054935T2 (hu) * | 2014-12-05 | 2021-10-28 | Aragon Pharmaceuticals Inc | Rákellenes készítmények |
| CN104546714A (zh) * | 2015-02-11 | 2015-04-29 | 江苏慧博生物科技有限公司 | 一种恩杂鲁胺胶束制剂及其制备方法 |
| US20180022819A1 (en) * | 2015-02-11 | 2018-01-25 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| CN104857517B (zh) * | 2015-05-14 | 2018-04-27 | 南京海纳医药科技股份有限公司 | 一种恩杂鲁胺软胶囊及其制备方法 |
| ES3063790T3 (en) | 2015-06-09 | 2026-04-20 | Lonza Sales Ag | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| CN105030685B (zh) * | 2015-07-21 | 2018-02-27 | 福格森（武汉）生物科技股份有限公司 | 一种恩杂鲁胺固体分散体口服制剂 |
| WO2017027665A1 (en) | 2015-08-12 | 2017-02-16 | Medivation Prostate Therapeutics, Inc. | Treatment of cancer using a combination of enzalutamide and a cyp3a4 inducer |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| ES3008933T3 (en) | 2015-09-29 | 2025-03-25 | Merz Pharmaceuticals Llc | Sustained release compositions of 4-aminopyridine |
| CN107126419B (zh) * | 2016-02-26 | 2020-06-19 | 石药集团中诺药业（石家庄）有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
| CA3036011A1 (en) | 2016-08-20 | 2018-03-01 | Ftf Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| KR102640668B1 (ko) * | 2017-04-13 | 2024-02-23 | 장 폴 레몬 | 잔토휴몰-계 조성물 |
| JP7172997B2 (ja) * | 2017-04-28 | 2022-11-16 | アステラス製薬株式会社 | エンザルタミドを含有する経口投与用医薬組成物 |
| TWI787284B (zh) | 2017-06-22 | 2022-12-21 | 美商西建公司 | 以b型肝炎病毒感染表徵之肝細胞癌之治療 |
| WO2019016747A1 (en) * | 2017-07-20 | 2019-01-24 | Dr. Reddy's Laboratories Limited | AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION |
| BR112020002705A2 (pt) * | 2017-08-08 | 2020-07-28 | Dr. Reddys Laboratories Limited | composições extrudadas de enzalutamida |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2019155416A2 (en) * | 2018-02-09 | 2019-08-15 | Kashiv Pharma Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
| ES2967689T3 (es) * | 2018-04-06 | 2024-05-03 | Capsugel Belgium Nv | Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)] |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| CN112955130A (zh) * | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
| WO2020122244A1 (ja) * | 2018-12-14 | 2020-06-18 | 富士フイルム株式会社 | 錠剤及びその製造方法 |
| CN109432016B (zh) * | 2018-12-26 | 2021-03-02 | 广州中医药大学(广州中医药研究院) | 一种恩杂鲁胺的三元固体制剂及其制备方法 |
| WO2020144650A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of prostate cancer |
| EP3917519A1 (en) | 2019-01-30 | 2021-12-08 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| KR20210122275A (ko) | 2019-01-30 | 2021-10-08 | 얀센 파마슈티카 엔.브이. | 분자 아형에 기초하여 전립선암을 치료하는 방법 |
| CA3139380A1 (en) | 2019-05-16 | 2020-11-19 | Leon-Nanodrugs Gmbh | Method for producing nanoparticles |
| CA3141534A1 (en) | 2019-05-23 | 2020-11-26 | Helm Ag | Nanoparticles comprising enzalutamide |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| US20220242829A1 (en) | 2019-06-27 | 2022-08-04 | Synthon B.V. | Process for preparation of enzalutamide |
| JP7812785B2 (ja) * | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| CA3149182A1 (en) * | 2019-09-23 | 2021-04-01 | Bionomics Limited | Therapeutic formulations and uses thereof |
| WO2021064123A1 (en) | 2019-10-03 | 2021-04-08 | Synthon B.V. | Pharmaceutical composition comprising enzalutamide |
| US11723898B2 (en) | 2019-11-04 | 2023-08-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| IL297939A (en) * | 2020-05-06 | 2023-01-01 | Disruptive Pharma Ab | New amorphous active pharmaceutical ingredients |
| AR118925A1 (es) * | 2020-05-13 | 2021-11-10 | Novocap S A | Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución |
| WO2021240206A1 (en) | 2020-05-24 | 2021-12-02 | Lotus International Pte. Ltd. | Enzalutamide formulation |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| CN114053243B (zh) * | 2020-08-05 | 2024-11-12 | 齐鲁制药有限公司 | 一种恩扎卢胺软胶囊及其制备方法 |
| WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| CA3191084A1 (en) * | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| IL301389A (en) * | 2020-09-18 | 2023-05-01 | Bristol Myers Squibb Co | Dosage forms for tyk2 inhibitors comprising swellable cores |
| CN112022812B (zh) * | 2020-11-03 | 2021-01-29 | 上海亚盛医药科技有限公司 | 一种包含杂环类化合物的组合物、其制备方法和应用 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| BR112023022789A2 (pt) | 2021-07-07 | 2024-02-27 | Bdr Pharmaceuticals International Private Ltd | Composição farmacêutica na forma de uma solução oral de enzalutamida, composição farmacêutica na forma de uma solução oral de enzalutamida e método para preparar uma solução oral de enzalutamida |
| CN115721612B (zh) * | 2021-08-26 | 2024-07-26 | 上海宣泰医药科技股份有限公司 | 一种恩扎卢胺固体制剂颗粒及其制备方法 |
| CN118251213A (zh) * | 2022-01-19 | 2024-06-25 | 四川科伦药物研究院有限公司 | 固体分散体及其制备方法和包含其的药物组合物 |
| CN114224832A (zh) * | 2022-02-11 | 2022-03-25 | 明度智云(浙江)科技有限公司 | 一种恩杂鲁胺注射剂及其制备方法和应用 |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2023244617A1 (en) * | 2022-06-13 | 2023-12-21 | Virginia Polytechnic Institute And State University | Amphiphilic cellulose derivatives, methods of making, and uses thereof |
| TW202416960A (zh) * | 2022-06-17 | 2024-05-01 | 美商特朗奎斯治療股份有限公司 | 2-芳基苯并咪唑化合物之調配物 |
| CN115887395A (zh) * | 2022-11-18 | 2023-04-04 | 上海药坦药物研究开发有限公司 | 恩杂鲁胺固体分散体制剂及其制备方法和应用 |
| EP4374853A1 (en) | 2022-11-22 | 2024-05-29 | Lotus Pharmaceutical Co., Ltd. | Solid formulation of enzalutamide |
| WO2024153733A1 (en) | 2023-01-18 | 2024-07-25 | Helm Ag | Crystalline nanoparticles comprising enzalutamide |
| WO2024191660A2 (en) * | 2023-03-10 | 2024-09-19 | Yale University | Compositions and methods for treating steroid hormone-related diseases or disorders |
| CN121038790A (zh) | 2023-03-16 | 2025-11-28 | 拜耳消费者护理股份有限公司 | 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂 |
| WO2025052925A1 (ja) * | 2023-09-08 | 2025-03-13 | 沢井製薬株式会社 | エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法 |
| KR20250058470A (ko) | 2023-10-23 | 2025-04-30 | 케이원팜 주식회사 | 안정성과 용출특성이 향상된 신규 엔잘루타마이드 함유 조성물 및 이의 제조방법 |
| EP4520322A1 (en) * | 2023-12-06 | 2025-03-12 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical compositions containing enzalutamide |
| WO2025125565A1 (en) | 2023-12-13 | 2025-06-19 | Krka, D.D., Novo Mesto | Tablet comprising enzalutamide |
| KR20250100928A (ko) | 2023-12-27 | 2025-07-04 | 케이원팜 주식회사 | 생체이용률이 개선된 엔잘루타마이드 약학 조성물 및 이의 제조방법 |
| CN118001243B (zh) * | 2024-01-31 | 2024-10-22 | 四川鲁徽制药有限责任公司 | 一种恩杂鲁胺口腔崩解片及其制备方法 |
| TR2024004340A1 (tr) * | 2024-04-05 | 2025-10-21 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Enzalutamidin katı dispersiyonu. |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| EP1741424B1 (en) | 1997-08-11 | 2018-10-03 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailabilty |
| ES2287971T3 (es) † | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| IN191496B (https=) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| PE20011184A1 (es) | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| CZ20032225A3 (cs) | 2001-02-27 | 2003-11-12 | Astrazeneca Ab | Farmaceutická formulace |
| SE0103424D0 (sv) † | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| GB2383042A (en) * | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| SE0103839D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| BR0307515A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| JP2005523360A (ja) * | 2002-04-18 | 2005-08-04 | アベシア・リミテッド | 共役分子の製造および製造において使用するための物質 |
| JP4249950B2 (ja) | 2002-06-28 | 2009-04-08 | 富士フイルム株式会社 | 紙管切断装置及び紙管切断方法 |
| AU2003209667A1 (en) * | 2003-02-21 | 2004-09-09 | Hetero Drugs Limited | Bicalutamide polymorphs |
| EP1730516A1 (en) | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| WO2006123223A1 (en) | 2005-05-19 | 2006-11-23 | Pfizer Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| US20070026073A1 (en) | 2005-07-28 | 2007-02-01 | Doney John A | Amorphous efavirenz and the production thereof |
| SI2656842T1 (sl) | 2006-03-27 | 2016-10-28 | The Regents Of The University Of California | Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji |
| US8613946B2 (en) | 2006-12-21 | 2013-12-24 | Isp Investment Inc. | Carotenoids of enhanced bioavailability |
| WO2008110534A1 (en) | 2007-03-13 | 2008-09-18 | Sandoz Ag | Pharmaceutical compositions of poorly soluble drugs |
| CN102083467B (zh) | 2008-03-11 | 2013-12-25 | Aska制药株式会社 | 固体分散体及其药物组合物、以及它们的制备方法 |
| MY172424A (en) † | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| DK2538785T3 (en) * | 2010-02-24 | 2018-05-22 | Medivation Prostate Therapeutics Llc | Methods for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
| NZ602288A (en) * | 2010-03-10 | 2014-02-28 | Abbvie Bahamas Ltd | Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| EP2858985B1 (en) | 2012-06-07 | 2018-04-18 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| US9515365B2 (en) * | 2012-08-10 | 2016-12-06 | Keyssa, Inc. | Dielectric coupling systems for EHF communications |
| KR20150053963A (ko) | 2012-09-11 | 2015-05-19 | 닥터 레디스 레보러터리즈 리미티드 | 엔잘루타마이드 다형태 및 그의 제조 |
| JP6404217B2 (ja) | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| EP2895150A1 (en) | 2012-09-11 | 2015-07-22 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| JP7172997B2 (ja) | 2017-04-28 | 2022-11-16 | アステラス製薬株式会社 | エンザルタミドを含有する経口投与用医薬組成物 |
| US20190208236A1 (en) | 2018-01-02 | 2019-07-04 | Source Digital, Inc. | Coordinates as ancillary data |
| WO2021064123A1 (en) | 2019-10-03 | 2021-04-08 | Synthon B.V. | Pharmaceutical composition comprising enzalutamide |
-
2013
- 2013-09-11 JP JP2015531335A patent/JP6404217B2/ja active Active
- 2013-09-11 EA EA201500314A patent/EA033374B9/ru not_active IP Right Cessation
- 2013-09-11 TW TW102132800A patent/TWI673051B/zh active
- 2013-09-11 CA CA2884795A patent/CA2884795C/en active Active
- 2013-09-11 EP EP13766437.1A patent/EP2895463A1/en not_active Withdrawn
- 2013-09-11 HR HRP20211423TT patent/HRP20211423T4/hr unknown
- 2013-09-11 CN CN201811517651.2A patent/CN109897004A/zh active Pending
- 2013-09-11 SM SM20210550T patent/SMT202100550T1/it unknown
- 2013-09-11 BR BR112015005432-3A patent/BR112015005432B1/pt active IP Right Grant
- 2013-09-11 ES ES20177837T patent/ES2892029T5/es active Active
- 2013-09-11 CN CN201380055471.6A patent/CN105358535B/zh active Active
- 2013-09-11 EP EP21190086.5A patent/EP3971167A1/en not_active Withdrawn
- 2013-09-11 LT LTEP20177837.0T patent/LT3725778T/lt unknown
- 2013-09-11 AU AU2013315619A patent/AU2013315619B2/en active Active
- 2013-09-11 EP EP20177837.0A patent/EP3725778B2/en active Active
- 2013-09-11 DK DK20177837.0T patent/DK3725778T4/da active
- 2013-09-11 EP EP24198653.8A patent/EP4450130A3/en active Pending
- 2013-09-11 KR KR1020157009040A patent/KR102225416B1/ko active Active
- 2013-09-11 US US14/023,637 patent/US20140100256A1/en not_active Abandoned
- 2013-09-11 WO PCT/US2013/059223 patent/WO2014043208A1/en not_active Ceased
- 2013-09-11 HK HK16100714.7A patent/HK1212701A1/zh unknown
- 2013-09-11 FI FIEP20177837.0T patent/FI3725778T4/fi active
- 2013-09-11 SI SI201331927T patent/SI3725778T1/sl unknown
- 2013-09-11 UA UAA201503119A patent/UA117353C2/uk unknown
- 2013-09-11 PL PL20177837.0T patent/PL3725778T5/pl unknown
- 2013-09-11 EA EA201991484A patent/EA201991484A1/ru unknown
- 2013-09-11 HU HUE20177837A patent/HUE057701T2/hu unknown
- 2013-09-11 RS RS20211117A patent/RS62676B2/sr unknown
- 2013-09-11 PT PT201778370T patent/PT3725778T/pt unknown
- 2013-09-11 IN IN2875DEN2015 patent/IN2015DN02875A/en unknown
- 2013-09-11 MX MX2015003140A patent/MX363974B/es active IP Right Grant
- 2013-09-11 EP EP23205739.8A patent/EP4324527A3/en not_active Withdrawn
- 2013-09-11 EP EP22197255.7A patent/EP4169908A1/en not_active Withdrawn
- 2013-09-11 US US14/023,878 patent/US20140179749A1/en not_active Abandoned
-
2014
- 2014-09-10 US US14/481,986 patent/US20140378517A1/en not_active Abandoned
-
2015
- 2015-03-08 IL IL237604A patent/IL237604B/en unknown
- 2015-03-11 MX MX2019003984A patent/MX2019003984A/es unknown
- 2015-03-11 MX MX2021000007A patent/MX2021000007A/es unknown
- 2015-03-11 PH PH12015500525A patent/PH12015500525A1/en unknown
- 2015-03-18 ZA ZA2015/01847A patent/ZA201501847B/en unknown
-
2016
- 2016-02-08 US US15/018,078 patent/US20170027910A1/en not_active Abandoned
- 2016-09-09 JP JP2016176557A patent/JP2016204392A/ja active Pending
- 2016-09-16 US US15/267,352 patent/US20170224624A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200316A patent/AU2018200316A1/en not_active Abandoned
- 2018-01-26 JP JP2018011759A patent/JP2018087206A/ja active Pending
- 2018-07-24 US US16/044,255 patent/US20190209476A1/en not_active Abandoned
-
2019
- 2019-04-01 US US16/371,618 patent/US20200060976A1/en not_active Abandoned
- 2019-08-08 JP JP2019146714A patent/JP6932746B2/ja active Active
-
2021
- 2021-08-17 JP JP2021132868A patent/JP2021178871A/ja active Pending
- 2021-09-14 CY CY20211100809T patent/CY1124729T1/el unknown
-
2022
- 2022-11-11 US US17/985,220 patent/US12447128B2/en active Active
- 2022-11-11 US US17/985,235 patent/US11839689B2/en active Active
-
2024
- 2024-10-30 US US18/931,464 patent/US20250049721A1/en active Pending
- 2024-12-04 US US18/967,829 patent/US12502357B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| IN2015DN00127A (https=) | ||
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
| IL239453A0 (en) | Preparations and methods for treating cancer using bacteria | |
| MY168032A (en) | Warm-Cool Beauty Treatment Device | |
| IN2014DN11201A (https=) | ||
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| ZA201408056B (en) | Compositions and methods for the treatment of mucositis | |
| EP2897689A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALOPEZIA | |
| IL239374A0 (en) | Preparations and methods for treating brain tumors | |
| GEP201706764B (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
| GEP20186920B (en) | Halogenated quinazolinthf-amines as pde1 inhibitors | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
| MY168958A (en) | Intermediates and processes for preparing compounds | |
| AU2013902004A0 (en) | Compositions for Therapy and Methods of Treatment | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| AU2012902296A0 (en) | Compositions for Therapy and Methods of Treatment | |
| UA80747U (ru) | Применение препарата октенисепт как средства для санации полостей суставов при лечении метаэпифизарного остеомиелита |